<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235351</url>
  </required_header>
  <id_info>
    <org_study_id>TIMI 56</org_study_id>
    <nct_id>NCT01235351</nct_id>
  </id_info>
  <brief_title>Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56</brief_title>
  <acronym>ELEVATE-TIMI56</acronym>
  <official_title>Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The TIMI Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The TIMI Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether higher as compared with lower maintenance doses of clopidogrel can
      adequately improve the degree of platelet inhibition in carriers of a reduced-function
      CYP2C19 allele.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in measurements of platelet inhibition</measure>
    <time_frame>Approximately every 2 weeks for 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Clopidogrel 75 mg daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 150 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 225 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 300 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype</description>
    <arm_group_label>Clopidogrel 75 mg daily</arm_group_label>
    <arm_group_label>Clopidogrel 150 mg daily</arm_group_label>
    <arm_group_label>Clopidogrel 225 mg daily</arm_group_label>
    <arm_group_label>Clopidogrel 300 mg daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (major):

          1. Between 18 and 75 years of age, inclusive.

          2. Have an indication for the use of clopidogrel defined as either spontaneous MI
             [hospitalized with final diagnosis of MI, excluding periprocedural or definite
             secondary MI (e.g., due to anemia or hypertensive emergency)] or PCI within the past 6
             months.

          3. Clinically stable and at least 4 weeks following the MI or PCI.

        Exclusion Criteria (major):

          1. Conditions that alter platelet function.

          2. Conditions that increase bleeding risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>TIMI Study Group</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2010</study_first_posted>
  <last_update_submitted>October 4, 2011</last_update_submitted>
  <last_update_submitted_qc>October 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>TIMI Study Group (Jessica Mega, MD, MPH)</name_title>
    <organization>TIMI Study Group</organization>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Genetics</keyword>
  <keyword>Platelet Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 7, 2012</submitted>
    <returned>January 14, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

